Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma

The advent of BTK inhibitors has changed the treatment of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The first-in-class BTK inhibitor ibrutinib has shown remarkable therapeutic effects and manageable toxicities in multiple clinical trials. The second-generation...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jing, Lu, Xueying, Li, Jianyong, Miao, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981798/
https://www.ncbi.nlm.nih.gov/pubmed/35379357
http://dx.doi.org/10.1186/s40364-022-00357-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981798/
https://www.ncbi.nlm.nih.gov/pubmed/35379357
http://dx.doi.org/10.1186/s40364-022-00357-5

Ejemplares similares